Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geraint Davies

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Cold Spring Harbor Perspectives in Medicine|September 20, 2014
Pharmacologic considerations in use and development of antituberculosis drugsGeraint Davies
JAMA Ophthalmology|October 31, 2024
Tuberculosis Uveitis-Consumed by UncertaintyNicholas A V Beare, Geraint Davies
Plos Medicine|July 10, 2019
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designsGeraint Davies, Martin Boeree, Dave Hermann, et al.
Journal of Pediatric Orthopedics. Part B|August 3, 2013
Successful operative management of an asymptomatic chest lesion in hereditary multiple exostosisHugh J S Pelc, Jenny Walker, Geraint Davies
Pharmaceutical Statistics|July 7, 2023
Determining the minimum duration of treatment in tuberculosis: An order restricted non-inferiority trial designAlessandra Serra, Pavel Mozgunov, Geraint Davies, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2015
Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future"Ana Requena-Méndez, Geraint Davies, David A J Moore
Chest|July 8, 2010
Insufficient evidence for chest CT scan in TB outbreak investigationElizabeth Joekes, Geraint Davies, Henry C Mwandumba, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2019
Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cureYanmin Hu, Henry Pertinez, Yingjun Liu, et al.
Systematic Reviews|July 14, 2017
Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)Marty Richardson, Jamie Kirkham, Kerry Dwan, et al.
Systematic Reviews|November 22, 2018
CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysisMarty Richardson, Jamie Kirkham, Kerry Dwan, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Cold Spring Harbor Perspectives in Medicine|September 20, 2014
Pharmacologic considerations in use and development of antituberculosis drugsGeraint Davies
JAMA Ophthalmology|October 31, 2024
Tuberculosis Uveitis-Consumed by UncertaintyNicholas A V Beare, Geraint Davies
Plos Medicine|July 10, 2019
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designsGeraint Davies, Martin Boeree, Dave Hermann, et al.
Journal of Pediatric Orthopedics. Part B|August 3, 2013
Successful operative management of an asymptomatic chest lesion in hereditary multiple exostosisHugh J S Pelc, Jenny Walker, Geraint Davies
Pharmaceutical Statistics|July 7, 2023
Determining the minimum duration of treatment in tuberculosis: An order restricted non-inferiority trial designAlessandra Serra, Pavel Mozgunov, Geraint Davies, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2015
Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future"Ana Requena-Méndez, Geraint Davies, David A J Moore
Chest|July 8, 2010
Insufficient evidence for chest CT scan in TB outbreak investigationElizabeth Joekes, Geraint Davies, Henry C Mwandumba, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2019
Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cureYanmin Hu, Henry Pertinez, Yingjun Liu, et al.
Systematic Reviews|July 14, 2017
Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol)Marty Richardson, Jamie Kirkham, Kerry Dwan, et al.
Systematic Reviews|November 22, 2018
CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysisMarty Richardson, Jamie Kirkham, Kerry Dwan, et al.
Pageof 4